Two-Pronged attack on deadly breast cancer shows promise
NCT ID NCT05795101
Summary
This study is testing whether a combination of two drugs, trastuzumab deruxtecan and durvalumab, can effectively shrink tumors before surgery in people with stage III inflammatory breast cancer that expresses the HER2 protein. The goal is to see if this pre-surgery treatment can eliminate all detectable cancer in the breast and lymph nodes. About 63 participants who haven't had prior treatment for this cancer will receive the drug combination for several months before undergoing standard surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.